Sandra Mazzoni, DO

Operationalizing Bispecifics with Other Sites

November 12th 2025

Panelists discuss how they collaborate with community oncology partners to expand bispecific antibody delivery, emphasizing that acute toxicities occur early at academic centers while maintenance dosing can be safely managed locally.

Real-world Outcomes with Talquetamab

November 12th 2025

Panelists discuss how they manage talquetamab-specific toxicities including dysgeusia and nail/skin changes through patient preparation, dietary modifications with umami-rich foods, emollients, and extended dosing intervals.

Dose Modifications with Bispecifics

November 5th 2025

Panelists discuss how they modify bispecific dosing intervals based on treatment response rather than dose intensity, extending administration frequency to every two or four weeks once patients achieve deeper responses.

Adverse Event Management with Bispecifics

November 5th 2025

Panelists discuss how they manage adverse events with bispecifics through universal IVIg administration from treatment initiation, comprehensive infection prophylaxis, and growth factor support for cytopenias.

Aligning Real-world and Clinical Trial Data

October 28th 2025

Panelists discuss how real-world outcomes with bispecific antibodies align closely with clinical trial data in terms of response rates, though with lower infection rates due to improved prophylaxis strategies.

Step-up Dosing with Bispecifics

October 28th 2025

Panelists discuss how they implement step-up dosing for bispecific antibodies, transitioning from inpatient to outpatient approaches using prophylactic tocilizumab and existing infrastructure from CAR-T and transplant programs.

Bispecific Antibody Therapies for Relapsed or Refractory Multiple Myeloma

October 21st 2025

Panelists discuss how they sequence bispecific antibodies with CAR-T therapy in relapsed/refractory multiple myeloma, preferring CAR-T before BCMa bispecifics and considering GPR-C5 targeting as bridging therapy.

Frontline Induction Therapy for Transplant-Ineligible or Transplant-Deferred Patients

October 21st 2025

Panelists discuss how they approach frontline therapy for transplant-ineligible or deferred patients, emphasizing reduced-intensity quadruplets for frail patients while considering transplant eligibility more broadly for fit older adults.

Exploring Minimal Residual Disease in Multiple Myeloma

October 14th 2025

Panelists discuss how they utilize minimal residual disease testing at various timepoints post-transplant to guide maintenance decisions and assess the potential for treatment discontinuation in sustained MRD-negative patients.

Selecting the Proper Maintenance Therapy

October 14th 2025

Panelists discuss how they approach maintenance therapy after transplant, tailoring treatment intensity based on risk stratification and considering clinical trials versus standard lenalidomide or doublet regimens.

Managing Adverse Events for Patients Receiving Quadruplet Induction Regimens

October 7th 2025

Panelists discuss how they manage adverse events in patients receiving quadruplet induction, particularly focusing on neuropathy prevention, dexamethasone dose reduction, infection prophylaxis, and IgG monitoring strategies.

Selecting Between Quadruplet Induction Regimens

October 7th 2025

Panelists discuss how data from the Perseus and Ischaemia trials inform their selection of quadruplet induction regimens and use of MRD negativity as a treatment endpoint before transplant.

Guideline Recommendations for Risk Stratification

September 30th 2025

Preferred Induction Regimen for Transplant-Eligible Patients with Newly-diagnosed Multiple Myeloma

September 30th 2025

Dr Mazzoni on the Use of Quadruplet Regimens in Newly Diagnosed Myeloma

October 23rd 2024

Sandra Mazzoni, DO, discusses the emerging role of quadruplet regimens in newly diagnosed multiple myeloma.

Cracking the “MGUS” Code Reveals Monoclonal Gammopathy of Clinical Significance:

November 1st 2022

When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment.